Everything below concerns half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Fluorodeoxyglucose ([18F]FDG or FDG) is commonly used to detect cancer, as cancer cells need sugar to grow. [18F]Sodium fluoride (Na18F) is widely used for detecting bone formation. Oxygen-15 (15O)-water is used to quantify myocardial blood flow. Carbon-11 (11C)-methionine is used to image brain tumors.
== Honors and awards == Bumpus has received numerous recognitions from the United States government for her work. In 2016, President Obama awarded her a Presidential Early Career Award for Scientists and Engineers, "the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers". She delivered the National Institute of General Medical Sciences (NIGMS) Director's Early-Career Investigator Lecture in 2017, and was the Congressional Biomedical Research Caucus's invited speaker in March 2018, lecturing about informing consumers about drug metabolism. Bumpus became a fellow of the American Association for the Advancement of Science, in its Section on Pharmaceutical Sciences, in 2021. In 2022, she was elected to the National Academy of Medicine. Additional awards she has received include:
==== Red-dome Cave 67: more royal dedications ==== Another nearby cave, the Red-domed Cave A (Cave 67) also has inscriptions mentioning a list of donors including a queen and six kings, among them Suvarnapuspa (ruled 600–625 CE) and his son Suvarnadeva (ruled 625–648 CE). Also included in the inscriptions are the names of King Tottika and his wife Svayamprabha (a Sanskrit name), who also appear in the Maya Cave of the Second Group (Cave 205), suggesting proximity in time of these two caves. The epigraphy also suggest dates later than the Cave of the Painters, with its more ancient inscription about the "painter Tutuka". The Red-dome cave contained a library in which were found very old manuscripts, including one of the oldest known manuscripts in Sanskrit.
Valve president and Half-Life director Gabe Newell coined the name "Gordon Freeman" during a conversation with the game's writer Marc Laidlaw in his car. Laidlaw had originally named the character "Dyson Poincaré", combining the names of physicist and philosopher Freeman Dyson and mathematician Henri Poincaré. The texture for Gordon's head was "too big of a job for just one person", so Valve designers combined references from four people. An earlier model of Gordon, known as "Ivan the Space Biker", had a full beard that was subsequently trimmed. Other iterations of Gordon's concept featured different glasses, a ponytail, and a helmet. Gordon wears a special full-body hazmat suit, known as the Hazardous Environment Suit (or HEV Suit). The suit is designed to protect the user from radiation, energy discharges, and blunt trauma during the handling of hazardous materials. The suit's main feature is its "high-impact reactive armor", an electrically powered armor system that, when charged, absorbs two-thirds of the damage that Gordon would ordinarily suffer in Half-Life and 80% in Half-Life 2. A fully charged suit can survive several dozen hits from small arms and even one direct hit from an RPG. The suit can be charged by various means, and has its own oxygen supply and medical injectors, such as morphine and a neurotoxin antidote. It comes with a built-in flashlight, a radio (which frequently picks up enemy communications), various tracking devices, a compass, and a Geiger counter.
Sources: en.wikipedia.org
Bromley is one of the major metropolitan centres identified in the London Plan. Bromley had one of the highest gross disposable household incomes (GDHI) in the UK, at £27,169 in 2018. Bromley was ranked fourth in Greater London by Retail Footprint in 2005, behind the West End, Croydon and Kingston upon Thames. Bromley competes with both Croydon and the Bluewater centre in Dartford as a shopping destination.
Gouy-Chapman theory describes the effect of a static surface charge on a surface's potential. "Gouy suggested that interfacial potential at the charged surface could be attributed to the presence of a number of ions of given charge attached to its surface, and to an equal number of ions of opposite charge in the solution." A positive surface charge will form a double layer, since negative ions in solution tend to balance the positive surface charge. Counter ions are not rigidly held, but tend to diffuse into the liquid phase until the counter potential set up by their departure restricts this tendency. The kinetic energy of the counter ions will, in part, affect the thickness of the resulting diffuse double layer. The relation between C, the counter ion concentration at the surface, and
== First Ministry == The Governor, Ken Michael, designated 17 principal executive offices of the Government under section 43(2) of the Constitution Acts Amendment Act 1899. The following ministers and parliamentary secretaries were then appointed to the positions, and served until the reconstitution of the Ministry on 14 December 2010. The list below is ordered by decreasing seniority within the Cabinet, as indicated by the Government Gazette and the Hansard index. Blue entries indicate members of the Liberal Party, green entries indicate members of the National Party, and grey indicates an Independent.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the usual choice, with results reported as area percent. Complementary methods such as size-exclusion chromatography and mass spectrometry are needed because a single separation cannot resolve every impurity class. Purity figures are therefore method dependent and should always be read alongside the technique used.